A prediction from a little over 13 months ago:

“...the next big change in the guidelines will come within two years, and recommend starting treatment when CD4’s fall below 500.”
AIDSmeds.com has a great overview of the latest updates to the HIV treatment guidelines.

It was also cool to finally see Kaletra demoted from a “preferred” to an “alternative” option for those starting treatment for the first time (except pregnant women, where it remains a preferred option).  Kaletra is sold by Abbott, and they’re still screwing us with that 400% price increase on Norvir.  I never understood why more docs and patients weren’t trying more lipid-friendly options like Reyataz.  Now they will.